News

FYI – True North Therapeutics has been purchased by a spin-off of Biogen. The new company Bioverativ’s focus is dedicated to developing treatments for rare diseases and plans to continue the TNT work with the monoclonal antibody TNT009. BIVV009 its new designation, is approaching a further clinical trial Phase 3. Phase Ia/Ib were done in Vienna, Austria. Bioverativ scientists are also working on the research stage development of TNT020, now BIVV020, a drug which would require less frequent dosing than the BIVV009.
15 August, 2017

 

New Entries in our RECENT CHANGES page
We have added links for two important papers from True North Therapeutics, San Fransisco, in our RECENT CHANGES page. In 2014 TNT published a paper entitled: “TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins”, and in 2015 another entitled: Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders (TNT009-01).

(Feb, 2016>


Dear CADdys living in the U.S:
I wanted to let you know about another opportunity with True North Therapeutics, the same group we collaborated with a couple of years ago to study our blood samples, and that led to a very impactful research paper on CAD.   They are creating a patient registry for CAD, called the COMPASS Registry.

To tell you more about the registry: it will be nationwide in scope, across all 50 states in the U.S. This registry will enable researchers to create a deeper understanding of the biology of CAD and the consequences for patients of living with this disease.

There are several benefits of joining the registry:
•         Integrate your CAD-related electronic health records all in one place, viewable on the COMPASS registry
•        Take a short health-related survey: think about your disease in a new way and compare your answers to others in the registry
•        Have a blood test at the Quest Patient Services Center nearest you, and support the development of new diagnostic tests and new medicines using what is learned.
•        This will be at no cost to you, and you will receive a $50 gift card to compensate you for your travel and time each time you give a blood sample.

Your information will be stored in a secure database, built and maintained by PatientCrossroads, a medical information technology company that has created and maintained similar patient registries for over 250 diseases.


You can click on the link here to register: http://www.compassregistry.org I hope you will decide to participate in this exciting opportunity.

Best Wishes,

Betty Usdan             (Feb, 2016)

Print Friendly, PDF & Email